Home Page
cover of participant diversity why it matters
participant diversity why it matters

participant diversity why it matters

John Gray

0 followers

00:00-05:16

Nothing to say, yet

Audio hosting, extended storage and much more

AI Mastering

Transcription

Research participant diversity is crucial for accurate and effective medical research. Limited enrollment of older patients, women, and minorities in clinical trials hinders the collection of relevant data and the development of treatments that work for everyone. This lack of diversity has negative consequences, including compromised research results, exclusion of certain groups from health benefits, and an inability to test the safety of innovations. Barriers such as disease prevalence, limited access, language barriers, and mistrust contribute to the problem. In the US, ethnic minorities make up a significant portion of the population but are underrepresented in clinical trials. In Canada, cultural, geographic, and socioeconomic differences further complicate the issue. Researchers can help address this by raising awareness, valuing participants, diversifying their own teams, and considering logistical factors. The lack of diversity in studies persists due to the failure to recognize Why does research participant diversity matter? Studies have long suggested that clinical trials do not enroll participants that represent the patients seen in the community. The limited enrollment of older patients, women and minorities in clinical trials has made it hard to collect and use data to treat these people. By recruiting participants from different ages, genders or ethnic backgrounds, health studies make treatments safer and work better for everyone. The danger? A lack of accurate representation of the entire population in medical research has a number of negative consequences. A threat to the quality and generalization of research results. Depriving excluded groups from the health benefits of trial participation. Inability to test the safety of health innovations. And failure to identify groups that have the greatest need for treatments. There are barriers to participation in minority groups. Certain diseases are prevalent in certain population subgroups. And it can be difficult for research teams to reach the right participants and reach their quotas. While studies acknowledge the barriers to diversity, long-term solutions to overcome them have proven elusive. This is particularly true of people of color and First Nations people. They may experience difficulties in transport. Limited access to research sites. Limited flexibility in working in care hours. Lack of access to surveillance technology. Strict inclusion and exclusion data. Language barriers, lack of information awareness and mistrust of medical researchers and the health care system all contribute to the lack of diversity in health studies. The importance of diversity in health research officially acknowledged in the United States. In the U.S., ethnic minorities make up 40% of the population. But only 7.5% of the 32,000 participants in trials of 53 new drugs approved in 2020 by the U.S. FDA. The proportion of white participants is in stark contrast to the disproportionate burden of chronic diseases among ethnic minorities. Clinical trials can't offer life-saving treatment options. In Canada, the problem is a little more complicated. Not only the vast differences in minority population sizes, but culture, geography and socioeconomic differences. In blunt terms, the reality that there has to be modifications to technologies used and treatments to be appropriate to physical racial traits. This does sound racist, but there is physical evidence. For example, pulse oximeters. Some have been shown to be inaccurate because of the differences in skin color. This can change dramatically with the right interventions. Researchers can play an important role in changing the situation. Raising patient awareness of studies, valuing study participants. The diversity among researchers themselves is important and makes patients more likely to trust their doctor and participate. The location of study sites is important, so are the logistics and access. Finally, research groups' inability to take seriously the social and financial costs of participating in studies remains one of the main reasons why the diversity of studies is such a persistent problem. PSYCHE Rebuilding bridges between researchers and communities. One click at a time. www.microsoft.com www.facebook.com www.youtube.com www.youtube.com www.youtube.com www.youtube.com www.youtube.com www.youtube.com www.youtube.com www.youtube.com www.youtube.com www.youtube.com www.youtube.com www.youtube.com

Listen Next

Other Creators